\-\ Texto\\:\\ \ \(0\)\
\-\ cbc\\:\\ normal\ \(0\)\
\-\ serum\\ chemistry\\ panel\\:\\ normal\ \(0\)\
\-\ ua\\:\\ blood\\ and\\ rbcs\\ noted\\,\\ otherwise\\ normal\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ back\\:\\ \\ no\\ cvat\ \(0\)\
\-\ lungs\\:\\ ctab\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ gu\\:\\ \\ normal\\ female\\ external\\ genitalia\ \(0\)\
\-\ abdominal\\ exam\\:\\ soft\\,\\ obvious\\ right\\ sided\\ mass\\,\\ relatively\\ non\\-tender\\.\\ \\ \\ \\ \\ \\ \\ \\ extremities\\:\\ \\ all\\ pulses\\ 2\\+\\ palpable\\,\\ equal\ \(0\)\
\-\ patient\\ underwent\\ right\\ radical\\ nephrectomy\\ and\\ exploration\\ of\\ left\\ kidney\\.\\ \\ uneventful\\ hospital\\ course\\.\\ \\ discharged\\ to\\ home\\ on\\ pod\\ \\#6\\ following\\ first\\ course\\ of\\ chemotherapy\\ by\\ pediatric\\ oncology\\ service\\.\ \(0\)\
\-\ ruq\\ ultrasound\\:\\ \\ a\\ large\\ mass\\ is\\ seen\\ in\\ the\\ right\\ upper\\ quadrant\\ in\\ the\\ expected\\ placement\\ of\\ the\\ right\\ kidney\\.\\ \\ \\ the\\ mass\\ appears\\ heterogeneous\\ with\\ multiple\\ cystic\\ components\\.\\ \\ the\\ mass\\ appears\\ somewhat\\ well\\ marginated\\.\\ \\ no\\ hypervascularity\\ is\\ seen\\.\\ \\ a\\ wedge\\ of\\ renal\\ parenchyma\\ can\\ be\\ seen\\ at\\ the\\ interface\\ of\\ the\\ tumor\\ and\\ the\\ liver\\ on\\ slide\\ \\#2\\.\ \(0\)\
\-\ abd\\.\\ ct\\:\\ \\ \\ a\\ 14cm\\,\\ heterogenous\\ renal\\ mass\\ extending\\ from\\ the\\ right\\ kidney\\ with\\ surrounding\\ rim\\ of\\ renal\\ parenchyma\\.\\ \\ there\\ are\\ multiple\\ low\\ density\\ collections\\ within\\ the\\ mass\\.\\ \\ there\\ is\\ no\\ evidence\\ of\\ fat\\ within\\ the\\ mass\\ or\\ calcifications\\ \\(suggesting\\ against\\ renal\\ angiomyolipoma\\ or\\ rhabdoid\\ tumor\\ of\\ the\\ kidney\\ respectively\\)\\.\\ \\ both\\ kidneys\\ demonstrate\\ contrast\\ enhancement\\ and\\ excretion\\.\\ \\ no\\ obvious\\ tumor\\ extensions\\ into\\ the\\ renal\\ vein\\ or\\ inferior\\ vena\\ cava\\ is\\ noted\\.\\ \\ mildly\\ enlarged\\ mesenteric\\ lymph\\ nodes\\ adjacent\\ to\\ the\\ kidney\\ suggest\\ possible\\ malignant\\ spread\\ or\\ may\\ be\\ reactive\\.\ \(0\)\
\-\ wilms\\â\\€\\™\\ tumor\\ \\(nephroblastoma\\)\\.\\ \\ negative\\ left\\ renal\\ involvement\\.\\ \\ negative\\ mesenteric\\ lymph\\ node\\ pathology\\.\ \(0\)\
\-\ renal\\ cell\\ carcinoma\ \(60\)\
\-\ wilms\\â\\€\\™\\ tumor\\ \\(nephroblastoma\\)\ \(0\)\
\-\ angiomyolipoma\ \(35\)\
\-\ soft\\-tissue\\ sarcoma\\ of\\ the\\ kidney\ \(0\)\
\-\ clear\\ cell\\ sarcoma\\ of\\ the\\ kidney\ \(0\)\
\-\ neuroblastoma\ \(81\)\
\-\ 13\\ year\\ old\\ caucasian\\ female\\ who\\ presented\\ to\\ the\\ er\\ following\\ a\\ two\\ week\\ history\\ of\\ right\\ sided\\ abdominal\\ pain\\ and\\ one\\ episode\\ of\\ hematuria\\ \\(patient\\ was\\ not\\ currently\\ menstruating\\)\\.\\ \\ patient\\ denies\\ fever\\,\\ weight\\ loss\\,\\ nausea\\,\\ vomiting\\.\ \(0\)\
\-\ wilms\\â\\€\\™\\ tumor\\ is\\ a\\ mixed\\ embryonal\\ neoplasm\\ that\\ is\\ the\\ most\\ common\\ intra\\-abdominal\\ tumor\\ and\\ renal\\ malignancy\\ in\\ childhood\\.\\ \\ it\\ is\\ the\\ fourth\\ most\\ common\\ pediatric\\ cancer1\\,2\\.\\ \\ \ \(0\)\
\-\ the\\ median\\ age\\ of\\ sporadic\\ wilms\\â\\€\\™\\ is\\ 44\\ months\\,\\ although\\ teenage\\ patients\\ \\(as\\ in\\ this\\ case\\ presentation\\)\\ may\\ present\\ with\\ it\\.\\ the\\ incidence\\ of\\ bilateral\\ tumours\\ is\\ between\\ 8\\â\\€\\“12\\%\\ and\\ the\\ gender\\ ratio\\ is\\ fairly\\ even\\ at\\ 1\\:1\\.2\\.\\ \\ the\\ mass\\ is\\ usually\\ smooth\\,\\ fixed\\ and\\ firm\\,\\ occasionally\\ extending\\ across\\ the\\ midline\\ of\\ the\\ abdomen\\.\\ \\ though\\ usually\\ asymptomatic\\,\\ 20\\-30\\%\\ of\\ patients\\ experience\\ hematuria\\,\\ abdominal\\ pain\\,\\ hypertension\\,\\ and\\ fever\\.\\ \\ symptoms\\ such\\ as\\ weight\\ loss\\,\\ cachexia\\,\\ or\\ bone\\ pain\\ are\\ uncommon\\ for\\ wilms\\â\\€\\™\\ tumor3\\.\ \(0\)\
\-\ wilms\\â\\€\\™\\ tumor\\ can\\ spread\\ locally\\ through\\ the\\ tumor\\ capsule\\ or\\ hematogenously\\ to\\ the\\ lungs\\,\\ liver\\,\\ or\\ the\\ other\\ kidney\\.\\ \\ it\\ may\\ progress\\ into\\ the\\ inferior\\ vena\\ cava\\ as\\ far\\ as\\ the\\ right\\ atrium3\\.\\ \ \(0\)\
\-\ wilms\\â\\€\\™\\ tumor\\,\\ which\\ is\\ intra\\-renal\\ in\\ development\\,\\ must\\ be\\ distinguished\\ from\\ neuroblastoma\\.\\ \\ neuroblastoma\\ typically\\ arises\\ in\\ the\\ adrenal\\ glands\\ and\\ is\\ the\\ second\\ most\\ common\\ childhood\\ solid\\ tumor\\.\\ \\ neuroblastomas\\ also\\ tend\\ to\\ have\\ calcifications\\,\\ another\\ difference\\ from\\ wilms\\â\\€\\™\\ tumors\\ that\\ may\\ be\\ discerned\\ radiologically1\\,\\ 4\\.\ \(0\)\
\-\ patients\\ with\\ chromosomal\\ aberrations\\ on\\ 11p13\\ and\\ 11p15\\ have\\ been\\ shown\\ to\\ be\\ at\\ increased\\ risk\\ of\\ wilms\\â\\€\\™\\ tumor\\.\\ \\ such\\ patients\\ may\\ present\\ with\\ other\\ conditions\\ that\\ include\\ aniridia\\,\\ mental\\ retardation\\,\\ macroglossia\\,\\ organomegaly\\,\\ or\\ genitourinary\\ anomalies3\\.\ \(0\)\
\-\ the\\ first\\ line\\ of\\ diagnostic\\ studies\\ for\\ wilms\\â\\€\\™\\ tumor\\ is\\ ultra\\ sound\\,\\ providing\\ a\\ non\\-invasive\\ means\\ of\\ evaluating\\ tumor\\ mass\\ in\\ the\\ abdomen\\.\\ it\\ can\\ be\\ helpful\\ in\\ ruling\\ out\\ an\\ extra\\-renal\\ mass\\ \\(neuroblastoma\\)\\ or\\ hydronephrosis5\\.\\ \\ ct\\ becomes\\ especially\\ useful\\ in\\ detection\\ of\\ bilateral\\ tumors\\ and\\ in\\ evaluation\\ of\\ other\\ abdominal\\ structures\\,\\ peritoneum\\,\\ and\\ lymph\\ nodes\\.\\ \\ on\\ ct\\ wilms\\â\\€\\™\\ tumor\\ appears\\ as\\ a\\ heterogenous\\,\\ enhancing\\ mass\\ with\\ less\\ than\\ 10\\%\\ showing\\ calcification\\.\\ \\ a\\ \\â\\€\\œclaw\\ sign\\"\\ of\\ the\\ displaced\\ renal\\ tissue\\ may\\ be\\ seen2\\.\\ \\ on\\ mri\\ the\\ tumors\\ are\\ hypointense\\ with\\ t1\\,\\ variable\\ with\\ t2\\,\\ and\\ enhance\\ poorly\\ with\\ gadolinium\\.\\ \\ gadolinium\\ is\\ given\\,\\ however\\,\\ to\\ evaluate\\ the\\ other\\ kidney\\ for\\ another\\ wilms\\â\\€\\™\\ mass2\\.\ \(0\)\
\-\ a\\ chest\\ xray\\ is\\ important\\ when\\ evaluating\\ a\\ patient\\ preoperatively\\ for\\ lung\\ metastasis\\.\\ \\ most\\ centers\\,\\ however\\,\\ prefer\\ the\\ use\\ of\\ chest\\ ct\\.\\ \\ though\\ chest\\ ct\\ is\\ a\\ sensitive\\ modality\\ for\\ wilms\\ tumor\\,\\ it\\ is\\ susceptible\\ to\\ false\\ positives\\ for\\ lung\\ metastasis\\ as\\ well\\ as\\ inter\\-reader\\ variability\\.\\ \\ histological\\ assessment\\ may\\ show\\ the\\ presence\\ of\\ nephrogenic\\ rests\\,\\ primordial\\ precursor\\ lesions\\ in\\ the\\ kidney\\,\\ common\\ in\\ the\\ setting\\ of\\ wilms\\â\\€\\™\\ tumor6\\.\ \(0\)\
\-\ nearly\\ all\\ patients\\ undergo\\ surgery\\ as\\ the\\ primary\\ treatment\\ method\\.\\ \\ chemotherapeutic\\ regimens\\ of\\ vincristine\\,\\ doxorubicin\\,\\ and\\ dactinomycin\\ with\\ or\\ without\\ radiation\\ therapy\\ \\(depending\\ on\\ the\\ stage\\ of\\ the\\ tumor\\)\\ are\\ used\\ in\\ treating\\ wilms\\â\\€\\™\\ tumor\\.\\ \\ \\ bilateral\\ renal\\ involvement\\ is\\ considered\\ stage\\ v\\ disease3\\.\ \(0\)\
\-\ relapse\\ rates\\ are\\ relatively\\ low\\ with\\ 10\\-15\\%\\ experiencing\\ relapse\\ in\\ patients\\ with\\ favorable\\ histologic\\ findings\\.\\ \\ they\\ increase\\ up\\ to\\ 50\\%\\ in\\ patients\\ with\\ anaplastic\\ findings3\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ wilms\\:\\ 0\\.08954556263008472\ \(0\)\
\-\ tumor\\:\\ 0\\.04047424540518578\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.04035708166482662\ \(0\)\
\-\ kidney\\:\\ 0\\.03397723989898431\ \(0\)\
\-\ renal\\:\\ 0\\.028978279339255862\ \(0\)\
\-\ neuroblastoma\\:\\ 0\\.019287691384634285\ \(0\)\
\-\ patients\\:\\ 0\\.017472937015307204\ \(0\)\
\-\ nephroblastoma\\:\\ 0\\.0152055911564033\ \(0\)\
\-\ relapse\\:\\ 0\\.01493971522941372\ \(0\)\
\-\ may\\:\\ 0\\.014808463411158993\ \(0\)\
\-\ mass\\:\\ 0\\.014755159228468633\ \(0\)\
\-\ \\,\\:\\ 0\\.012832757056124234\ \(0\)\
\-\ \\:\\:\\ 0\\.01275705209921744\ \(0\)\
\-\ is\\:\\ 0\\.012058154389740165\ \(0\)\
\-\ lymph\\:\\ 0\\.011680166170241467\ \(0\)\
\-\ as\\:\\ 0\\.011671128721391671\ \(0\)\
\-\ angiomyolipoma\\:\\ 0\\.011629699272769417\ \(0\)\
\-\ or\\:\\ 0\\.011303868498461711\ \(0\)\
\-\ \\%\\:\\ 0\\.011248990030169343\ \(0\)\
\-\ tumors\\:\\ 0\\.010868114077891088\ \(0\)\
\-\ childhood\\:\\ 0\\.010853691283823989\ \(0\)\
\-\ it\\:\\ 0\\.010840002170050884\ \(0\)\
\-\ appears\\:\\ 0\\.010769962147169012\ \(0\)\
\-\ evaluating\\:\\ 0\\.010733804544966318\ \(0\)\
\-\ be\\:\\ 0\\.010411170500459936\ \(0\)\
\-\ vena\\:\\ 0\\.010214580096654869\ \(0\)\
\-\ cava\\:\\ 0\\.010153567292167466\ \(0\)\
\-\ common\\:\\ 0\\.010096014500931814\ \(0\)\
\-\ cancer1\\,2\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ 8\\â\\€\\“12\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ 1\\:1\\.2\\.\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ tumor3\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ atrium3\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ intra\\-renal\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ discerned\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ radiologically1\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ aberrations\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ 11p13\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ 11p15\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ anomalies3\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ extra\\-renal\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ hydronephrosis5\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ seen2\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ mass2\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ inter\\-reader\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ variability\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ tumor6\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ disease3\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ findings3\\:\\ 0\\.009949795060910269\ \(0\)\
\-\ heterogenous\\:\\ 0\\.00989774633210651\ \(0\)\
\-\ obvious\\:\\ 0\\.009742006215883144\ \(0\)\
\-\ abdominal\\:\\ 0\\.009642976244343635\ \(0\)\
\-\ spread\\:\\ 0\\.009330445139598822\ \(0\)\
\-\ pediatric\\:\\ 0\\.009289024962018243\ \(0\)\
\-\ cvat\\:\\ 0\\.009167461900007395\ \(0\)\
\-\ extensions\\:\\ 0\\.009167461900007395\ \(0\)\
\-\ neuroblastomas\\:\\ 0\\.009167461900007395\ \(0\)\
\-\ ultra\\:\\ 0\\.009167461900007395\ \(0\)\
\-\ primordial\\:\\ 0\\.009167461900007395\ \(0\)\
\-\ hematuria\\:\\ 0\\.009149761826566008\ \(0\)\
\-\ gadolinium\\:\\ 0\\.009149761826566008\ \(0\)\
\-\ though\\:\\ 0\\.008946925869180318\ \(0\)\
\-\ most\\:\\ 0\\.008906704928794924\ \(0\)\
\-\ mesenteric\\:\\ 0\\.008894630024301008\ \(0\)\
\-\ other\\:\\ 0\\.00889227335757313\ \(0\)\
\-\ nodes\\:\\ 0\\.008712621594503922\ \(0\)\
\-\ 14cm\\:\\ 0\\.008709826337808564\ \(0\)\
\-\ aniridia\\:\\ 0\\.008709826337808564\ \(0\)\
\-\ dactinomycin\\:\\ 0\\.008709826337808564\ \(0\)\
\-\ sarcoma\\:\\ 0\\.00858890097036172\ \(0\)\
\-\ menstruating\\:\\ 0\\.008385128739104523\ \(0\)\
\-\ teenage\\:\\ 0\\.008385128739104523\ \(0\)\
\-\ hematogenously\\:\\ 0\\.008385128739104523\ \(0\)\
\-\ macroglossia\\:\\ 0\\.008385128739104523\ \(0\)\
\-\ chemotherapeutic\\:\\ 0\\.008385128739104523\ \(0\)\
\-\ another\\:\\ 0\\.008293126111656519\ \(0\)\
\-\ relatively\\:\\ 0\\.008253867098762909\ \(0\)\
\-\ stage\\:\\ 0\\.008228068688325837\ \(0\)\
\-\ parenchyma\\:\\ 0\\.008215279213076002\ \(0\)\
\-\ cachexia\\:\\ 0\\.008133273715047852\ \(0\)\
\-\ preoperatively\\:\\ 0\\.008133273715047852\ \(0\)\
\-\ prefer\\:\\ 0\\.008133273715047852\ \(0\)\
\-\ pod\\:\\ 0\\.00792749317690569\ \(0\)\
\-\ positives\\:\\ 0\\.00792749317690569\ \(0\)\
\-\ non\\-invasive\\:\\ 0\\.007753508210960705\ \(0\)\
\-\ precursor\\:\\ 0\\.007753508210960705\ \(0\)\
\-\ hypervascularity\\:\\ 0\\.00760279557820165\ \(0\)\
\-\ ruling\\:\\ 0\\.00760279557820165\ \(0\)\
\-\ nephrogenic\\:\\ 0\\.00760279557820165\ \(0\)\
\-\ \\#\\:\\ 0\\.0075658840156679185\ \(0\)\
\-\ chemistry\\:\\ 0\\.00746985761470686\ \(0\)\
\-\ slide\\:\\ 0\\.00746985761470686\ \(0\)\
\-\ tumours\\:\\ 0\\.007350940554144979\ \(0\)\
\-\ regimens\\:\\ 0\\.007350940554144979\ \(0\)\
\-\ lungs\\:\\ 0\\.00730426320085841\ \(0\)\
\-\ course\\:\\ 0\\.00727885201682989\ \(0\)\
\-\ claw\\:\\ 0\\.00724336698777441\ \(0\)\
\-\ metastasis\\:\\ 0\\.007220648592099157\ \(0\)\
\-\ calcifications\\:\\ 0\\.007171927211360615\ \(0\)\
\-\ rhabdoid\\:\\ 0\\.007145160016002818\ \(0\)\
\-\ chromosomal\\:\\ 0\\.007145160016002818\ \(0\)\
\-\ rests\\:\\ 0\\.007145160016002818\ \(0\)\
\-\ in\\:\\ 0\\.007134264618627342\ \(0\)\
\-\ sided\\:\\ 0\\.007132114250895362\ \(0\)\
\-\ right\\:\\ 0\\.007123501087779816\ \(0\)\
\-\ involvement\\:\\ 0\\.007069838954013129\ \(0\)\
\-\ susceptible\\:\\ 0\\.007054818359486411\ \(0\)\
\-\ bilateral\\:\\ 0\\.007021956194066966\ \(0\)\
\-\ doxorubicin\\:\\ 0\\.006971175050057832\ \(0\)\
\-\ chest\\:\\ 0\\.006923461625476925\ \(0\)\
\-\ weight\\:\\ 0\\.0069140988377897625\ \(0\)\
\-\ rbcs\\:\\ 0\\.006893304991946148\ \(0\)\
\-\ the\\:\\ 0\\.006865652964965615\ \(0\)\
\-\ providing\\:\\ 0\\.0068204624172987765\ \(0\)\
\-\ ct\\:\\ 0\\.006745505944650355\ \(0\)\
\-\ genitalia\\:\\ 0\\.006687524453803988\ \(0\)\
\-\ 20\\-30\\:\\ 0\\.006687524453803988\ \(0\)\
\-\ liver\\:\\ 0\\.006650612891270256\ \(0\)\
\-\ locally\\:\\ 0\\.0066265005020316676\ \(0\)\
\-\ are\\:\\ 0\\.006573780319015812\ \(0\)\
\-\ peritoneum\\:\\ 0\\.006568607393242107\ \(0\)\
\-\ 10\\-15\\:\\ 0\\.006568607393242107\ \(0\)\
\-\ can\\:\\ 0\\.006562829635899784\ \(0\)\
\-\ inferior\\:\\ 0\\.0065447321926841145\ \(0\)\
\-\ fever\\:\\ 0\\.006526552204406243\ \(0\)\
\-\ embryonal\\:\\ 0\\.006513539487859\ \(0\)\
\-\ distinguished\\:\\ 0\\.006513539487859\ \(0\)\
\-\ retardation\\:\\ 0\\.006513539487859\ \(0\)\
\-\ sound\\:\\ 0\\.006513539487859\ \(0\)\
\-\ vincristine\\:\\ 0\\.006513539487859\ \(0\)\
\-\ extending\\:\\ 0\\.0064846931125051846\ \(0\)\
\-\ first\\:\\ 0\\.006472874570622691\ \(0\)\
\-\ intra\\-abdominal\\:\\ 0\\.006461033826871537\ \(0\)\
\-\ gender\\:\\ 0\\.006461033826871537\ \(0\)\
\-\ genitourinary\\:\\ 0\\.006461033826871537\ \(0\)\
\-\ centers\\:\\ 0\\.006461033826871537\ \(0\)\
\-\ difference\\:\\ 0\\.006410862537288203\ \(0\)\
\-\ gu\\:\\ 0\\.006316752369185437\ \(0\)\
\-\ exploration\\:\\ 0\\.006316752369185437\ \(0\)\
\-\ favorable\\:\\ 0\\.006272485198583539\ \(0\)\
\-\ uneventful\\:\\ 0\\.006229888891605156\ \(0\)\
\-\ excretion\\:\\ 0\\.006229888891605156\ \(0\)\
\-\ sporadic\\:\\ 0\\.006229888891605156\ \(0\)\
\-\ oncology\\:\\ 0\\.0061492354333860305\ \(0\)\
\-\ wedge\\:\\ 0\\.0061492354333860305\ \(0\)\
\-\ organomegaly\\:\\ 0\\.0061492354333860305\ \(0\)\
\-\ means\\:\\ 0\\.006110971831043276\ \(0\)\
\-\ false\\:\\ 0\\.006110971831043276\ \(0\)\
\-\ histologic\\:\\ 0\\.006110971831043276\ \(0\)\
\-\ anaplastic\\:\\ 0\\.006073963001671954\ \(0\)\
\-\ normal\\:\\ 0\\.0060479117589124195\ \(0\)\
\-\ radical\\:\\ 0\\.006038129256395904\ \(0\)\
\-\ xray\\:\\ 0\\.006038129256395904\ \(0\)\
\-\ such\\:\\ 0\\.006030096591062872\ \(0\)\
\-\ histological\\:\\ 0\\.006003398264672706\ \(0\)\
\-\ method\\:\\ 0\\.006003398264672706\ \(0\)\
\-\ ctab\\:\\ 0\\.0059697041753389805\ \(0\)\
\-\ interface\\:\\ 0\\.0059697041753389805\ \(0\)\
\-\ treating\\:\\ 0\\.0059697041753389805\ \(0\)\
\-\ experiencing\\:\\ 0\\.005936986865098289\ \(0\)\
\-\ marginated\\:\\ 0\\.005905191292901115\ \(0\)\
\-\ usually\\:\\ 0\\.005857625855229704\ \(0\)\
\-\ soft\\-tissue\\:\\ 0\\.005814849636384708\ \(0\)\
\-\ arises\\:\\ 0\\.005786274232339234\ \(0\)\
\-\ negative\\:\\ 0\\.005760993592268338\ \(0\)\
\-\ glands\\:\\ 0\\.005731206326956128\ \(0\)\
\-\ seen\\:\\ 0\\.00571770072822017\ \(0\)\
\-\ abdomen\\:\\ 0\\.005714185695024145\ \(0\)\
\-\ \\(\\:\\ 0\\.005707146821339756\ \(0\)\
\-\ panel\\:\\ 0\\.005678700665968664\ \(0\)\
\-\ fairly\\:\\ 0\\.005653336268844445\ \(0\)\
\-\ \\)\\:\\ 0\\.005637430976064488\ \(0\)\
\-\ detection\\:\\ 0\\.0056042560070614445\ \(0\)\
\-\ rates\\:\\ 0\\.0056042560070614445\ \(0\)\
\-\ loss\\:\\ 0\\.005599241924307989\ \(0\)\
\-\ lung\\:\\ 0\\.0055872666371077784\ \(0\)\
\-\ service\\:\\ 0\\.005580493694197074\ \(0\)\
\-\ median\\:\\ 0\\.005580493694197074\ \(0\)\
\-\ fixed\\:\\ 0\\.005580493694197074\ \(0\)\
\-\ respectively\\:\\ 0\\.005557221361011141\ \(0\)\
\-\ following\\:\\ 0\\.005474667622801689\ \(0\)\
\-\ nephrectomy\\:\\ 0\\.0054686529462916215\ \(0\)\
\-\ tend\\:\\ 0\\.0054686529462916215\ \(0\)\
\-\ all\\:\\ 0\\.005455809231221875\ \(0\)\
\-\ progress\\:\\ 0\\.005447555730702284\ \(0\)\
\-\ far\\:\\ 0\\.005447555730702284\ \(0\)\
\-\ ruq\\:\\ 0\\.0054268456419119945\ \(0\)\
\-\ against\\:\\ 0\\.005406508728252086\ \(0\)\
\-\ however\\:\\ 0\\.005371033985546434\ \(0\)\
\-\ low\\:\\ 0\\.005363810503084423\ \(0\)\
\-\ ratio\\:\\ 0\\.005347608329639705\ \(0\)\
\-\ nearly\\:\\ 0\\.005309982573130007\ \(0\)\
\-\ experience\\:\\ 0\\.005291629840769082\ \(0\)\
\-\ modality\\:\\ 0\\.005291629840769082\ \(0\)\
\-\ v\\:\\ 0\\.005291629840769082\ \(0\)\
\-\ sensitive\\:\\ 0\\.005238297013623995\ \(0\)\
\-\ capsule\\:\\ 0\\.0052210651037698326\ \(0\)\
\-\ cell\\:\\ 0\\.005210475646910804\ \(0\)\
\-\ collections\\:\\ 0\\.005187371014436107\ \(0\)\
\-\ assessment\\:\\ 0\\.005187371014436107\ \(0\)\
\-\ across\\:\\ 0\\.005154653704195416\ \(0\)\
\-\ variable\\:\\ 0\\.005138643958154833\ \(0\)\
\-\ ua\\:\\ 0\\.005122858131998242\ \(0\)\
\-\ non\\-tender\\:\\ 0\\.0051072900483274345\ \(0\)\
\-\ abd\\:\\ 0\\.0051072900483274345\ \(0\)\
\-\ occasionally\\:\\ 0\\.005076783646083733\ \(0\)\
\-\ equal\\:\\ 0\\.005047080137824846\ \(0\)\
\-\ becomes\\:\\ 0\\.005047080137824846\ \(0\)\
\-\ useful\\:\\ 0\\.005032516475481835\ \(0\)\
\-\ depending\\:\\ 0\\.005018138342550199\ \(0\)\
\-\ that\\:\\ 0\\.004997677410470056\ \(0\)\
\-\ pulses\\:\\ 0\\.004989920168503453\ \(0\)\
\-\ helpful\\:\\ 0\\.004989920168503453\ \(0\)\
\-\ 44\\:\\ 0\\.004948873166053255\ \(0\)\
\-\ for\\:\\ 0\\.004937526965977755\ \(0\)\
\-\ 2\\+\\:\\ 0\\.004935515990379437\ \(0\)\
\-\ a\\:\\ 0\\.004923925304745613\ \(0\)\
\-\ on\\:\\ 0\\.004902196472000642\ \(0\)\
\-\ undergo\\:\\ 0\\.004896367505065792\ \(0\)\
\-\ adrenal\\:\\ 0\\.004883614056697921\ \(0\)\
\-\ setting\\:\\ 0\\.004871003107941572\ \(0\)\
\-\ conditions\\:\\ 0\\.0047981605332942006\ \(0\)\
\-\ episode\\:\\ 0\\.004774888200108268\ \(0\)\
\-\ somewhat\\:\\ 0\\.004740855425649253\ \(0\)\
\-\ components\\:\\ 0\\.004729735452237276\ \(0\)\
\-\ firm\\:\\ 0\\.004729735452237276\ \(0\)\
\-\ uncommon\\:\\ 0\\.004718723968100295\ \(0\)\
\-\ poorly\\:\\ 0\\.004707818876777794\ \(0\)\
\-\ expected\\:\\ 0\\.004697018141996585\ \(0\)\
\-\ suggesting\\:\\ 0\\.004686319785388748\ \(0\)\
\-\ fourth\\:\\ 0\\.004665222569799411\ \(0\)\
\-\ enhance\\:\\ 0\\.004665222569799411\ \(0\)\
\-\ serum\\:\\ 0\\.0046548200245342605\ \(0\)\
\-\ caucasian\\:\\ 0\\.004604198618027091\ \(0\)\
\-\ into\\:\\ 0\\.004589901507809722\ \(0\)\
\-\ home\\:\\ 0\\.004584569111580286\ \(0\)\
\-\ hypointense\\:\\ 0\\.004574880913283004\ \(0\)\
\-\ noted\\:\\ 0\\.004572056858809466\ \(0\)\
\-\ reactive\\:\\ 0\\.0045652751687368315\ \(0\)\
\-\ mental\\:\\ 0\\.004500231023323021\ \(0\)\
\-\ kidneys\\:\\ 0\\.00443873194286696\ \(0\)\
\-\ showing\\:\\ 0\\.00443873194286696\ \(0\)\
\-\ displaced\\:\\ 0\\.004430213652082104\ \(0\)\
\-\ discharged\\:\\ 0\\.0044217591693178175\ \(0\)\
\-\ incidence\\:\\ 0\\.0044217591693178175\ \(0\)\
\-\ node\\:\\ 0\\.004413367545742741\ \(0\)\
\-\ must\\:\\ 0\\.004396769185257757\ \(0\)\
\-\ well\\:\\ 0\\.004363613889319754\ \(0\)\
\-\ present\\:\\ 0\\.004356678902780318\ \(0\)\
\-\ 13\\:\\ 0\\.004356310797251961\ \(0\)\
\-\ to\\:\\ 0\\.004338163629782028\ \(0\)\
\-\ important\\:\\ 0\\.004332714087523616\ \(0\)\
\-\ cbc\\:\\ 0\\.004309600620995917\ \(0\)\
\-\ even\\:\\ 0\\.00429445048518086\ \(0\)\
\-\ from\\:\\ 0\\.004288157042282886\ \(0\)\
\-\ mixed\\:\\ 0\\.004235805181647326\ \(0\)\
\-\ smooth\\:\\ 0\\.0042216079105334885\ \(0\)\
\-\ development\\:\\ 0\\.004200641335394735\ \(0\)\
\-\ have\\:\\ 0\\.004177061124977633\ \(0\)\
\-\ mildly\\:\\ 0\\.004107639606538001\ \(0\)\
\-\ suggest\\:\\ 0\\.004107639606538001\ \(0\)\
\-\ external\\:\\ 0\\.004101280895795049\ \(0\)\
\-\ rim\\:\\ 0\\.004082416921784055\ \(0\)\
\-\ denies\\:\\ 0\\.004070013850028304\ \(0\)\
\-\ multiple\\:\\ 0\\.004062767502210539\ \(0\)\
\-\ increase\\:\\ 0\\.004045609263105995\ \(0\)\
\-\ especially\\:\\ 0\\.003969752886476818\ \(0\)\
\-\ female\\:\\ 0\\.0039655988068799854\ \(0\)\
\-\ line\\:\\ 0\\.003964123607118987\ \(0\)\
\-\ pathology\\:\\ 0\\.003947402291334404\ \(0\)\
\-\ at\\:\\ 0\\.003920191262409592\ \(0\)\
\-\ placement\\:\\ 0\\.003914684981093712\ \(0\)\
\-\ evaluate\\:\\ 0\\.003898675235053129\ \(0\)\
\-\ considered\\:\\ 0\\.003893388723413822\ \(0\)\
\-\ no\\:\\ 0\\.003884623705209038\ \(0\)\
\-\ nausea\\:\\ 0\\.003882889408896538\ \(0\)\
\-\ shown\\:\\ 0\\.0038673213252257304\ \(0\)\
\-\ patient\\:\\ 0\\.0038672321937534442\ \(0\)\
\-\ solid\\:\\ 0\\.0038468923843187125\ \(0\)\
\-\ currently\\:\\ 0\\.0038218654571242176\ \(0\)\
\-\ diagnostic\\:\\ 0\\.0038218654571242176\ \(0\)\
\-\ use\\:\\ 0\\.003812008030522915\ \(0\)\
\-\ hypertension\\:\\ 0\\.003802235950677413\ \(0\)\
\-\ 4\\.\\:\\ 0\\.0037973814564343086\ \(0\)\
\-\ extremities\\:\\ 0\\.0037829420078339593\ \(0\)\
\-\ midline\\:\\ 0\\.003731523800607811\ \(0\)\
\-\ malignancy\\:\\ 0\\.0037269635189633357\ \(0\)\
\-\ structures\\:\\ 0\\.003713392195073041\ \(0\)\
\-\ second\\:\\ 0\\.003704434464152345\ \(0\)\
\-\ er\\:\\ 0\\.0036999821184514237\ \(0\)\
\-\ used\\:\\ 0\\.0036999821184514237\ \(0\)\
\-\ vomiting\\:\\ 0\\.0036823463194637475\ \(0\)\
\-\ within\\:\\ 0\\.003679754872203344\ \(0\)\
\-\ 50\\:\\ 0\\.0036692979871826236\ \(0\)\
\-\ hospital\\:\\ 0\\.003631034384839868\ \(0\)\
\-\ studies\\:\\ 0\\.0036021455053940853\ \(0\)\
\-\ \\â\\€\\œ\\:\\ 0\\.0036021455053940853\ \(0\)\
\-\ clear\\:\\ 0\\.003566057125447681\ \(0\)\
\-\ of\\:\\ 0\\.003550341559306645\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.0035464956622968456\ \(0\)\
\-\ pain\\:\\ 0\\.003533661966808357\ \(0\)\
\-\ calcification\\:\\ 0\\.0035008867025475496\ \(0\)\
\-\ presence\\:\\ 0\\.0035008867025475496\ \(0\)\
\-\ risk\\:\\ 0\\.0034934612272675917\ \(0\)\
\-\ vein\\:\\ 0\\.0034897667291355723\ \(0\)\
\-\ malignant\\:\\ 0\\.003486084284852484\ \(0\)\
\-\ they\\:\\ 0\\.0034751084949066658\ \(0\)\
\-\ otherwise\\:\\ 0\\.0034642384124450843\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.0034570494188948813\ \(0\)\
\-\ palpable\\:\\ 0\\.0034183081744918625\ \(0\)\
\-\ typically\\:\\ 0\\.0034045437579074177\ \(0\)\
\-\ quadrant\\:\\ 0\\.0033943294965982553\ \(0\)\
\-\ sign\\:\\ 0\\.0033413617401400345\ \(0\)\
\-\ presentation\\:\\ 0\\.0033221226122924176\ \(0\)\
\-\ underwent\\:\\ 0\\.0033094763380115337\ \(0\)\
\-\ given\\:\\ 0\\.0033063367861358266\ \(0\)\
\-\ enlarged\\:\\ 0\\.0032907687024650184\ \(0\)\
\-\ neoplasm\\:\\ 0\\.003284601101480731\ \(0\)\
\-\ week\\:\\ 0\\.0032754124360363747\ \(0\)\
\-\ less\\:\\ 0\\.003266297973276165\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.0032602623002213173\ \(0\)\
\-\ although\\:\\ 0\\.0032572565243528255\ \(0\)\
\-\ 10\\:\\ 0\\.00325126888075272\ \(0\)\
\-\ possible\\:\\ 0\\.003248286928763061\ \(0\)\
\-\ out\\:\\ 0\\.003187419725573946\ \(0\)\
\-\ back\\:\\ 0\\.003181790446216114\ \(0\)\
\-\ density\\:\\ 0\\.0031733988226410373\ \(0\)\
\-\ surrounding\\:\\ 0\\.003170615422533595\ \(0\)\
\-\ radiation\\:\\ 0\\.0031650691304315305\ \(0\)\
\-\ 2\\.\\:\\ 0\\.0030670927108355055\ \(0\)\
\-\ between\\:\\ 0\\.0030569927045420355\ \(0\)\
\-\ t1\\:\\ 0\\.0030569927045420355\ \(0\)\
\-\ adjacent\\:\\ 0\\.003049476573514974\ \(0\)\
\-\ and\\:\\ 0\\.0030475565304551658\ \(0\)\
\-\ enhancing\\:\\ 0\\.0030247782538202696\ \(0\)\
\-\ show\\:\\ 0\\.0029606726122930315\ \(0\)\
\-\ age\\:\\ 0\\.0029355647015172756\ \(0\)\
\-\ fat\\:\\ 0\\.002933309619505229\ \(0\)\
\-\ 6\\:\\ 0\\.002880496796134169\ \(0\)\
\-\ there\\:\\ 0\\.0028706897437132924\ \(0\)\
\-\ ultrasound\\:\\ 0\\.0028613121726933444\ \(0\)\
\-\ primary\\:\\ 0\\.0028570928475120726\ \(0\)\
\-\ evaluation\\:\\ 0\\.0028016239230550877\ \(0\)\
\-\ cystic\\:\\ 0\\.002781752491254806\ \(0\)\
\-\ two\\:\\ 0\\.0027622248731557623\ \(0\)\
\-\ when\\:\\ 0\\.0027622248731557623\ \(0\)\
\-\ through\\:\\ 0\\.002739229140429874\ \(0\)\
\-\ carcinoma\\:\\ 0\\.0027335526749614745\ \(0\)\
\-\ t2\\:\\ 0\\.002729784163375115\ \(0\)\
\-\ include\\:\\ 0\\.0027055908442779756\ \(0\)\
\-\ months\\:\\ 0\\.002634245253600527\ \(0\)\
\-\ blood\\:\\ 0\\.0026325181405296833\ \(0\)\
\-\ presented\\:\\ 0\\.0026290718228243895\ \(0\)\
\-\ been\\:\\ 0\\.0026239219971376875\ \(0\)\
\-\ one\\:\\ 0\\.0026136923062196884\ \(0\)\
\-\ up\\:\\ 0\\.002593506942499123\ \(0\)\
\-\ enhancement\\:\\ 0\\.002585201767633223\ \(0\)\
\-\ lesions\\:\\ 0\\.002581896734022514\ \(0\)\
\-\ therapy\\:\\ 0\\.0025786013501587052\ \(0\)\
\-\ evidence\\:\\ 0\\.0025287162340483947\ \(0\)\
\-\ than\\:\\ 0\\.002527143177108661\ \(0\)\
\-\ who\\:\\ 0\\.002514637030633975\ \(0\)\
\-\ both\\:\\ 0\\.0024629796734606333\ \(0\)\
\-\ symptoms\\:\\ 0\\.0024036766104945134\ \(0\)\
\-\ bone\\:\\ 0\\.0023966531393452254\ \(0\)\
\-\ increased\\:\\ 0\\.0023594636363427264\ \(0\)\
\-\ soft\\:\\ 0\\.0023486758058617946\ \(0\)\
\-\ surgery\\:\\ 0\\.0023419853999551636\ \(0\)\
\-\ upper\\:\\ 0\\.002327404633599005\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.002324773704268897\ \(0\)\
\-\ tissue\\:\\ 0\\.002286028429404733\ \(0\)\
\-\ without\\:\\ 0\\.0022708952216232052\ \(0\)\
\-\ demonstrate\\:\\ 0\\.0022194719428138155\ \(0\)\
\-\ mri\\:\\ 0\\.0022158869694295933\ \(0\)\
\-\ contrast\\:\\ 0\\.0021588890370292384\ \(0\)\
\-\ left\\:\\ 0\\.002158251172173622\ \(0\)\
\-\ exam\\:\\ 0\\.0021187741985886433\ \(0\)\
\-\ case\\:\\ 0\\.0021100501499630594\ \(0\)\
\-\ large\\:\\ 0\\.002108964370012505\ \(0\)\
\-\ findings\\:\\ 0\\.0020528633586794124\ \(0\)\
\-\ treatment\\:\\ 0\\.0019521636112876826\ \(0\)\
\-\ \\.\\:\\ 0\\.0019232254319104076\ \(0\)\
\-\ also\\:\\ 0\\.0019013765165577328\ \(0\)\
\-\ which\\:\\ 0\\.0018003889246529894\ \(0\)\
\-\ with\\:\\ 0\\.0017167655633956733\ \(0\)\
\-\ by\\:\\ 0\\.0016059491007278494\ \(0\)\
\-\ not\\:\\ 0\\.0013937005324401075\ \(0\)\
\-\ an\\:\\ 0\\.0013337075217660606\ \(0\)\
\-\ history\\:\\ 0\\.0013320705843195071\ \(0\)\
\-\ was\\:\\ 0\\.0011154373839883597\ \(0\)\
\-\ this\\:\\ 0\\.001084804981167193\ \(0\)\
\-\ year\\:\\ 0\\.001079125586086811\ \(0\)\
\-\ old\\:\\ 0\\.0009875108316729736\ \(0\)\
